Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...
Researchers engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five ...
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) plus pertuzumab as first-line therapy for unresectable or ...
The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated non small cell lung cancer (NSCLC), enabling five-minute administration with fewer infusion reactions. I ...
ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...
An international study shows that artificial intelligence (AI) can outperform radiologists in detecting pancreatic cancer on ...
Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab regimen increased objective response rates from 37% to 49%, tripled median ...
BioNTech SE and Bristol Myers Squibb have partnered to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A in over 10 solid tumor indications. The ...
The FDA has granted Breakthrough Device Designation to PreveCol, a blood test for early colorectal cancer detection developed by Amadix. PreveCol excels in identifying precancerous lesions more ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell lung cancer, supported by early ARTEMIS 001 data showing durable responses in ...
New findings, published in Cellular and Molecular Gastroenterology and Hepatology, show that the transcription factor CREB drives the progression from alcohol-induced pancreatic inflammation to cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback